| Hazard Information | Back Directory | [Uses]
WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase[1][2][3]. | [in vivo]
WKYMVM-NH2 TFA (8?mg/kg; six times; for 5 days) ameliorates DSS-induced ulcerative colitis[3].
WKYMVM-NH2 TFA affects cytokine (IL-17, IFN-γ, IL-6, IL-1β and TNF-α) profiles in the DSS colitis model[3].
| Animal Model: | Six-week-old C57BL/6 mice, DSS model[3] | | Dosage: | 8?mg/kg | | Administration: | Subcutaneously injected, six subcutaneous administrations at 12-h intervals, for 5 days | | Result: | Attenuated the DSS-induced increase in the bleeding score and the stool score. |
| [References]
[1] Christophe T, et al. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem. 2001 Jun 15;276(24):21585-93. DOI:10.1074/jbc.M007769200
[2] Christophe T, et al. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol. 2002 Nov;56(5):470-6. DOI:10.1046/j.1365-3083.2002.01149.x
[3] Sang Doo Kim, et al. The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis. Exp Mol Med. 2013 Sep; 45(9): e40. DOI:10.1038/emm.2013.77 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|